Menu Search
Equities

Atrion Corp

AN2:BER

Atrion Corp

Actions
Health CareMedical Equipment and Services
  • Price (EUR)384.00
  • Today's Change-12.00 / -3.03%
  • Shares traded5.00
  • 1 Year change-30.81%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.

  • Revenue in USD (TTM)169.33m
  • Net income in USD19.41m
  • Incorporated1996
  • Employees712.00
  • Location
    Atrion CorpOne Allentown ParkwayALLEN 75002United StatesUSA
  • Phone+1 (972) 390-9800
  • Fax+1 (302) 655-5049
  • Websitehttps://atrioncorp.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.